FESTUS EBONKA: Open Payments
NPI 1932241007 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$475 in 20 payments from 10 companies in 2025. Trend: 2023 $275 · 2024 $589 · 2025 $475
Food & beverage: $475
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 5 | $122 |
| Neurocrine BioSciences, Inc. | 3 | $86 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $50 |
| AstraZeneca Pharmaceuticals LP | 2 | $47 |
| Forte Bio-Pharma LLC | 2 | $46 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $29 |
| Alkermes, Inc. | 1 | $28 |
| PFIZER INC. | 1 | $27 |
| ABBVIE INC. | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
Products named: ABILIFY ASIMTUFII, INGREZZA, CAPLYTA, AIRSUPRA, PROLATE, XIFAXAN, REXULTI, ARISTADA.
Industry payments across NV — which companies pay providers there.
